Rapid HIV testing bioLytical offers the INSTI rapid HIV test with results in as little as 60 seconds, presenting a compelling value proposition for healthcare providers, payers, and public health organizations seeking point-of-care solutions.

Diversified infectious panel Recent and upcoming launches include multiplex HIV-1/2 and syphilis antibody testing, and HCV antibody tests, creating cross-sell opportunities to clinics and laboratories seeking streamlined, multi-disease rapid diagnostics.

Global regulatory reach With FDA, Health Canada, and CE marks, bioLytical has established regulatory credibility that facilitates entry into new markets and strengthens proposals to distributors and procurement teams in regulated regions.

Expansion through partnerships Strategic collaborations and social impact activities, such as test donations and NGO partnerships, open channels for government and non-profit contracts, large-scale tenders, and international distribution deals.

Private company growth Revenue tier and growth recognition in British Columbia, plus ongoing R&D for self-test and pipeline products, indicate a scalable platform with potential enterprise and regional partner opportunities, including contract services to adapt the INSTI platform.